

Recommendations for the use of albumin and immunoglobulins

Giancarlo Liumbruno¹, Francesco Bennardello², Angela Lattanzio³, Pierluigi Piccoli⁴, Gina Rossetti⁵ as Italian Society of Transfusion Medicine and Immunohaematology (SIMTI) Working Party

¹UU.OO.CC. di Immunoematologia e Medicina Trasfusionale e Patologia Clinica, Ospedale "San Giovanni Calibita" Fatebenefratelli, Roma; ²Servizio di Immunoematologia e Medicina Trasfusionale, Azienda Ospedaliera "Civile-Maria Paternò Arezzo", Ragusa; ³Servizio di Immunoematologia e Medicina Trasfusionale, Azienda Ospedaliera di Carbonara di Bari; ⁴Servizio di Immunoematologia e Medicina Trasfusionale, Azienda Ospedaliera di Verona; ⁵Servizio di Immunoematologia e Medicina Trasfusionale, Azienda Ospedaliera di Trento; Italy

Albumin

Introduction

Human albumin is a physiological plasma-expander; its limited availability and high cost make it essential to define recommendations for its appropriate use, as an alternative to other therapeutic strategies including solutions of crystalloids and non-protein colloids, and have also stimulated numerous studies, which have sometimes reached contradictory conclusions¹⁻⁸.

In 1998 a meta-analysis of 30 randomised trials suggested that the use of albumin was associated with an increased mortality rate among critically ill patients^{9,10}. This conclusion, also reached by two subsequent Cochrane reviews^{11,12}, was not confirmed by a meta-analysis in 2001 or by more recent studies¹³⁻²³.

A review in 2006 showed that renal damage can be induced by the use of hydroxyethyl starch and gelatine in sepsis and surgery²⁴.

The limited power of all these studies could lie in their having combined results from heterogeneous types of patients with different baseline albumin concentrations^{25,26}.

Notions of physiology

Albumin is the main factor determining the oncotic pressure of blood and, therefore, the regulation of plasma volume and tissue fluid balance; it is also involved in the transport of numerous endogenous substances, such as unconjugated bilirubin and hormones, and exogenous ones, including drugs²⁷⁻²⁹.

The body content of albumin is 4-5 g/kg, distributed predominantly in the extracellular space; 30-40% is found in the intravascular compartment (40-

50 g/L of plasma) and is responsible for about 80% of the osmotic pressure of the plasma¹⁹.

It has not been clearly determined whether there is a threshold concentration of albumin below which its oncotic function is compromised to a clinically relevant degree; there is, however, a consensus that oncotic activity remains physiologically adequate at values of albumin ≥ 2 g/dL and total proteins ≥ 3.5 g/dL.

The infusion of human albumin causes, within a few minutes, the movement of fluids from the interstitial space into the circulation; this passage of fluids is, however, limited or absent in dehydrated patients unless the dehydration is corrected.

The half-life of endogenous albumin is about 3 weeks, while that of blood-derived albumin is only 12-16 hours and is reduced notably in conditions of increased capillary permeability.

Preparations of albumin

Solutions of albumin are prepared from the plasma of healthy donors. The albumin is pasteurised at 60 °C for 10 hours³⁰. It can be infused independently of the recipient's blood group.

Preparations of 5%, 20% and 25% have been registered. The solutions of 5% human albumin have an osmotic pressure almost identical to that of normal plasma; the 20% and 25% solutions are hyperosmotic. All the preparations contain 130 - 160 mEq of sodium per litre.

Indications

On the basis of clinical evidence, the use of albumin can be indicated in acute conditions³¹, in which it is necessary to expand the volume and maintain the circulation, and in some chronic states of low serum albumin; there are some widely shared

and fully agreed indications for the appropriate use of human albumin and indications that are occasionally appropriate, that is, when other criteria are fulfilled (table I)^{32,33}. Albumin is also used in all cases in which there is a contraindication to the use of non-protein colloids.

Acute conditions

Haemorrhagic shock

(occasionally appropriate indication)

Albumin is used as a **second choice** (*Grade of recommendation: 1A*)^{8-16,18,32-38}, when **solutions of crystalloids or non-protein colloids (first choice treatment)** have already been used at maximum doses without having produced a clinically adequate response and in cases in

which non-protein colloids are contraindicated.

Crystalloid and colloid solutions must not be considered as blood replacements when oxygen-transporting capacity is reduced. Albumin 5% must be used.

Major surgery

(occasionally appropriate indication)

The use of albumin may be indicated in subjects undergoing major surgery (> 40% resection of the liver, extensive intestinal resection) when, after normalisation of circulatory volume, the serum albumin is < 2 g/dL (*Grade of recommendation 2C+*)^{14,15,17,18,31-33,39,40}.

The use of albumin in the immediate post-operative period is never advised for any other type of operation.

Table I –Indications for the use of albumin

Indication	Notes	GoR
<i>Appropriate indications (for which there is widespread consensus)</i>		
Paracentesis	5 g of albumin/L ascitic fluid removed, after paracentesis of volumes > 5 L.	1C+
Therapeutic plasmapheresis	For exchanges of > 20 mL/kg in one session or > 20 mL/kg/week in more than one session.	2C+
Spontaneous bacterial peritonitis	In association with antibiotics.	1C+
<i>Occasionally appropriate indications (when other criteria are fulfilled)</i>		
Heart surgery	Last-choice treatment after crystalloids and non-protein colloids.	2C+
Major surgery	Albumin should not be used in the immediate post-operative period. Only indication for use: serum albumin < 2 g/dL after normalisation of circulatory volume.	2C+
Cirrhosis of the liver with refractory ascites	Generally ineffective, except in patients with serum albumin < 2 g/dL.	2C
Contraindications to the use of non-protein colloids	- pregnancy and breastfeeding; - perinatal period and early infancy; - acute liver failure; - moderate-severe renal failure (particularly when anuria/oliguria); - dialysis treatment in the presence of severe abnormalities of haemostasis and baseline albumin < 2–2.5 g/dL; - intracranial haemorrhage; - hypersensitivity.	2C
Haemorrhagic shock	Only in the case of : - lack of response to crystalloids or colloids; - contraindication to the use of non-protein colloids.	1A
Hepatorenal syndrome	In association with vasoconstricting drugs.	2B
Nephrotic syndrome	Only in patients with albumin < 2 g/dL with hypovolaemia and/or pulmonary oedema.	2C
Organ transplantation	In the post-operative period after liver transplantation to control ascites and peripheral oedema, IC to replace the loss of ascitic fluid from the drainage tubes, if albumin < 2.5 g/dL with a haematocrit > 30%.	1C
Burns	In the case of burns of > 30% body surface area, after the first 24 hours.	2C+

Dose

The dose needed to obtain a serum albumin ≥ 2.5 g/dL is calculated using the following formula:

$$\text{Dose (g)} = [\text{desired albumin concentration (2.5 g/dL)} - \text{actual albumin concentration (g/dL)}] \times \text{plasma volume (0.8 \times kg)}$$

GoR: Grade of Recommendation

Burns**(occasionally appropriate indication)**

There is no indication to use albumin in the resuscitation phase in the first 24 hours after burn injuries, that is, in the period of increased capillary permeability. Subsequently, albumin 5% is indicated, using different doses according to the amount of body surface area (BSA) involved (*Grade of recommendation: 2C+*)^{7,15,18,38,41,42}:

- BSA 30 - 50%: 0.3 mL x kg x % of burnt BSA, in 24 hours;
- BSA 50 - 70%: 0.4 mL x kg x % of burnt BSA, in 24 hours;
- BSA 70 - 100%: 0.5 mL x kg x % of burnt BSA, in 24 hours.

In the post-resuscitation phase, once the problems of circulatory volume caused by the marked capillary permeability have been overcome, albumin 5% or 20% is infused at a dose of 1 - 2 g/kg/die if:

- albumin < 1 g/dL (end-point 2 g/dL);
- albumin 1-2 g/dL and the patient cannot tolerate an enteral diet or has massive tissue oedema or pulmonary dysfunction, which could be aggravated by a low oncotic pressure (end-point 2 g/dL).

Heart surgery**(occasionally appropriate indication)**

Albumin can be used as a post-operative volume expander, as a last choice of treatment after crystalloids or non-protein colloids, following heart surgery.

Crystalloids are the first choice for priming the circuitry in the case of extracorporeal circulation^{43,44}; the association with non-protein colloids can be preferable to avoid the accumulation of fluid in the pulmonary interstitium (*Grade of recommendation: 2C+*)^{14,43-46}.

Organ transplantation**(occasionally appropriate indication)**

Albumin can be useful in the post-operative period following liver transplantation, in order to control the ascites and peripheral oedema and to replace the loss of ascitic fluid through the drainage tubes; it is administered in the following circumstances: albumin < 2.5 g/dL, pulmonary capillary pressure < 12 mmHg, haematocrit > 30% (*Grade of recommendation: 1C*)^{13,32,33,47}.

There is not definitive evidence that albumin and/or non-protein colloids are effective during or after kidney transplants^{32,33}.

Therapeutic plasmapheresis**(appropriate indication)**

The use of albumin is appropriate only for the exchange of large volumes of plasma: more than 20 mL/kg in a single session or 20 mL/kg/week in successive sessions. In the case of exchange of small volumes of plasma, it is worth considering, for cost-benefit reasons, crystalloid solutions or the association of albumin/crystalloids (*Grade of recommendation: 2C+*)^{32,33,48-50}.

Chronic states of low albuminaemia**Liver cirrhosis with refractory ascites**

There is a lack of consensus on the use of albumin in advanced liver disease, but there is some evidence to support its use in the following circumstances:

- 1) ascites not responsive to diuretics;
- 2) large volume paracentesis;
- 3) hepatorenal syndrome;
- 4) spontaneous bacterial peritonitis.

Ascites not responsive to diuretics**(occasionally appropriate indication)**

This is the most controversial indication. Albumin is usually ineffective, except in patients with serum albumin < 2 g/dL. Subjects with ascites are at risk of diuretic-induced hyponatraemia and deteriorating renal function (prerenal uraemia); the risk is highest in subjects with hypoalbuminaemia and advanced disease. Albumin can improve the response to diuretics and prevent complications related to the treatment, favouring the passage of fluid from the peritoneal space to the vascular compartment; it can also correct the altered pharmacokinetics of loop diuretics typically seen in patients with cirrhosis. The patients who can gain most benefit from this treatment are those in the most precarious clinical condition, with hypovolaemia and ascites that responds poorly to diuretics: in these cases albumin can be administered even when the concentration of albumin is > 2.5 g/dL (*Grade of recommendation: 2C*)⁵¹⁻⁵⁹.

Large volume paracentesis**(appropriate indication)**

Total paracentesis is considered the treatment of choice in subjects with refractory or tense ascites. A paracentesis volume > 5L can, in some cases, lead to hypovolaemia and particularly unfavourable haemodynamic changes, with the possible risk of:

- deterioration of renal function;

- dilutional hyponatraemia;
- rapidly recurrent ascites;
- shortened survival.

In order to reduce the risks in such cases, albumin is used at a dose of 5 g/L of fluid removed, in a single administration at the end of the paracentesis. The 20% - 25% preparations are preferable (*Grade of recommendation: 1C+*)^{32,33,55,60-64}.

Hepatorenal syndrome (HRS) (occasionally appropriate indication)

HRS consists of a deterioration in renal function, which occurs in 10% of subjects with advanced cirrhosis and ascites⁶⁵. It is considered the extreme outcome of the haemodynamic dysfunction of cirrhosis, associated with impaired cardiac function due to the reduced venous return.

The deterioration in renal function can be rapidly progressive (type 1 HRS) or stable-slowly progressive (type 2 HRS); the mortality rate of patients with type 1 HRS is very high, with a median survival (without therapy) of less than 1 month.

The treatment of choice is liver transplantation. Medical treatment consists of a combination of vasoconstrictors and high doses of albumin (*Grade of recommendation: 2B*)^{32,33,65-68}.

Spontaneous bacterial peritonitis (appropriate indication)

Spontaneous bacterial peritonitis is a common and severe complication of ascitic cirrhosis and occurs in about 20 - 30% of patients; it is characterised by spontaneous infection of the ascitic fluid, in the absence of abdominal sources of infection, and can evolve, in about 30% of the cases, into HRS.

Albumin 20% - 25%, in association with antibiotics, can be used in the treatment of spontaneous bacterial peritonitis and reduces the probability of the onset of HRS and mortality (*Grade of recommendation: 1C+*)⁶⁹⁻⁷⁴.

Nephrotic syndrome (occasionally appropriate indication)

Short-term infusion of albumin 20% - 25%, in association with diuretics, is appropriate in patients with serum albumin < 2 g/dL, with marked hypovolaemia and/or acute pulmonary oedema and/or acute renal failure (*Grade of recommendation: 2C*)^{32,33,75-77}.

Malnutrition syndromes (occasionally appropriate indication)

Albumin must not be used for nutritional purposes; the correct treatment is enteral nutrition, using peptide-based formulas, or total parenteral nutrition.

However, the administration of albumin can be useful in patients with diarrhoea who cannot tolerate enteral nutrition in the following circumstances: volume of diarrhoea > 2 L/die; serum albumin < 2 g/dL; continuing diarrhoea despite the administration of short-chain peptides and mineral formulas; no other cause to explain the diarrhoea (*Grade of recommendation: 2C*)^{32,33}.

Inappropriate indications

Albumin is not indicated in the following conditions (table II)^{32,33}:

- albuminaemia > 2.5 g/dL (with the exception of the particular cases listed above);
- hypoalbuminaemia in the absence of oedema and acute hypotension;
- malnutrition;
- wound healing;
- non-haemorrhagic shock^{78,79};
- ascites responsive to diuretics;
- burns in the first 24 hours;
- protein-losing enteropathies and malabsorption;
- acute or chronic pancreatitis;
- haemodialysis⁸⁰⁻⁸³;
- cerebral ischaemia⁸⁴;
- acute normovolaemic haemodilution in surgery;
- ovarian hyperstimulation syndrome⁸⁵⁻⁸⁷.

Calculation of the dose of albumin to administer

$$\text{Dose (g)} = (\text{2.5 g/dL} - \text{actual albumin concentration}) \times (\text{kg} \times 0.8) \text{ (table I).}$$

Legend:

2.5 g/dL: desired concentration of albumin; kg: body weight; 0.8: coefficient to calculate the volume of plasma.

Monitoring indices for clinical auditing

The use of albumin therapy in the following circumstances:

- albuminaemia > 2.5 g/dL;
- malnutrition;
- non-haemorrhagic shock;
- ascites responsive to diuretics;
- acute or chronic pancreatitis;

Side effects and adverse reactions

Albumin is usually well tolerated. However, immediate allergic-type reactions are possible with fever, shivers, nausea, vomiting, urticaria, hypotension, increased salivation, and effects on respiration and heart rate^{32,33,88}. Very fast infusions (20 - 50 mL/minute) can cause a brusque fall in systemic blood pressure and, in elderly subjects and those at risk of congestive heart failure, it can induce manifest congestive heart failure, particularly when the more concentrated solutions of albumin are used. Albumin is considered a safe blood derivative from the point of view of transmission of infections, although there are some questions about the potential transmission of prions.

Recommendations

It is recommended that the details of the product infused, including the batch number, are registered in the patient's clinical records.

Table II – Inappropriate indications for the use of albumin.

1)	Albuminaemia > 2.5 g/dL
2)	Chronic hypoalbuminaemia in the absence of oedema and/or acute hypotension
3)	Malnutrition
4)	Wound healing
5)	Non-haemorrhagic shock
6)	Ascites responsive to diuretics
7)	Burns, in the first 24 h
8)	Protein losing enteropathies and malabsorption
9)	Acute or chronic pancreatitis
10)	Haemodialysis
11)	Cerebral ischaemia
12)	Acute normovolaemic haemodilution in surgery
13)	Ovarian hyperstimulation syndrome

References

- Virgilio RW, Rice CL, Smith DE, et al. Crystalloid vs. colloid resuscitation: is one better? A randomized clinical study. *Surgery* 1979; **85**: 129-39.
- Goldwasser P, Feldman J. Association of serum albumin and mortality risk. *J Clin Epidemiol* 1997; **50**: 693-703.
- No authors listed. Treatment of systematic capillary leak syndrome [letter]. *Lancet* 1988; **2**: 1946.
- Dollery C. *Therapeutic Drugs*. Edinburgh, UK, Churchill Livingstone; 1991. Vol. 1, p. H27-H30.
- Yim JM, Vermeulen LC, Erstad BL, et al. Albumin and protein colloid solution use in US academic health centers. *Arch Intern Med* 1995; **155**: 2450-5.
- Vermeulen LC Jr, Ratko TA, Erstad BL, et al. A paradigm for consensus. The University Hospital Consortium guidelines for the use of albumin, non protein colloid and crystalloid solutions. *Arch Intern Med* 1995; **155**: 373-9.
- Gore DC, Dalton JM, Gehr TW. Colloid infusions reduce glomerular filtration in resuscitated burn victims. *J Trauma* 1996; **40**: 356-60.
- Schierhout G, Roberts I. Fluid resuscitation with colloid or crystalloid solutions in critically ill patients: a systematic review of randomized trials. *BMJ* 1998; **316**: 961-4.
- Offringa M. Excess mortality after human albumin administration in critically ill patients. Clinical and pathophysiological evidence suggests albumin is harmful [editorial]. *BMJ* 1998; **317**: 223-4.
- Cochrane Injuries Group Albumin Reviewers: Human albumin administration in critically ill patients: systematic review of randomized controlled trials. *BMJ* 1998; **317**: 235-40.
- Bunn F, Lefebvre C, Li Wan Po A, et al. Human albumin solution for resuscitation and volume expansion in critically ill patients: The albumin reviewers. *Cochrane Database Syst Rev* 2000; **2**: CD001208.
- Alderson P, Bunn F, Lefebvre C, et al. Human albumin solution for resuscitation and volume expansion in critically ill patients. *Cochrane Database Syst Rev* 2001; **1**: CD001208.
- Wilkes M, Navickis RJ. Patient survival after albumin administration. A meta-analysis of randomized, controlled trials. *Ann Intern Med* 2001; **135**: 149-64.
- Haynes GR, Navickis RJ, Wilkes MM. Albumin administration: what is the evidence of clinical benefit? A systematic review of randomized controlled trials. *Eur J Anaesthesiol* 2003; **20**: 771-93.
- Alderson P, Bunn F, Lefebvre C, et al. Human albumin solution for resuscitation and volume expansion in critically ill patients. *Cochrane Database Syst Rev* 2004; **4**: CD001208.
- Finfer S, Bellomo R, Boyce N, et al. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. *N Engl J Med* 2004; **350**: 2247-56.
- Vincent JL, Navickis RJ, Wilkes MM. Morbidity in hospitalized patients receiving human albumin: a meta-analysis of randomized, controlled trials. *Crit Care Med* 2004; **32**: 2029-38.
- Liberati A, Moja L, Moschetti I, et al. Human albumin solution for resuscitation and volume expansion in critically ill patients. *Intern Emerg Med* 2006; **1**: 243-5.
- Dubois MJ, Vincent JL. Use of albumin in the intensive care unit. *Curr Opin Crit Care* 2002; **8**: 299-301.
- Martin GS. A new twist on albumin therapy in the intensive care unit, again [editorial]. *Crit Care Med* 2006; **34**: 2677-8.
- Dubois MJ, Orellana-Jimenez C, Melot C, et al. Albumin administration improves organ function in critically ill hypoalbuminemic patients: A prospective, randomized, controlled, pilot study. *Crit Care Med* 2006; **34**: 2536-40.
- Barron ME, Wilkes MM, Navickis RJ. A Systematic review of the comparative safety of colloids. *Arch Surg* 2004; **139**: 552-63.
- Bellomo R, Morimatsu H, French C, et al. The effects of saline or albumin resuscitation on acid-base status and serum electrolytes. *Crit Care Med* 2006; **34**: 2891-7.
- Davidson IJ. Renal impact of fluid management with

- colloids: a comparative review. *Eur J Anaesthesiol* 2006; **23**: 721-38.
- 25) SAFE Study Investigators, Finfer S, Bellomo R, McEvoy S, et al. Effect of baseline serum albumin concentration on outcome of resuscitation with albumin or saline in patients in intensive care units: analysis of data from the saline versus albumin fluid evaluation (SAFE) study. *BMJ* 2006; **333**: 1044-9.
 - 26) Vincent JL, Sakr Y, Reinhart K, et al. Is albumin administration in the acutely ill associated with increased mortality? Results of the SOAP study. *Crit Care* 2005; **9**: 745-54.
 - 27) Evans TW. Review article: albumin as a drug: biological effects of albumin unrelated to oncotic pressure. *Aliment Pharmacol Ther* 2002; **16** (Suppl 5): 6-11.
 - 28) Mendez CM, McClain CJ, Marsano LS. Albumin therapy in clinical practice. *Nutr Clin Pract* 2005; **20**: 314-20.
 - 29) Quinlan GJ, Martin GS, Evans TW. Albumin: biochemical properties and therapeutic potential. *Hepatology* 2005; **41**: 1211-9.
 - 30) Burnouf T. Modern plasma fractionation. *Transfus Med Rev* 2007; **21**: 101-17.
 - 31) Vincent JL, Dubois MJ, Navickis RJ, Wilkes MM. Hypoalbuminemia in acute illness: is there a rationale for intervention? A meta-analysis of cohort studies and controlled trials. *Ann Surg* 2003; **237**: 319-34.
 - 32) Prinoth O, Strada P. Proposta di linee guida al corretto uso dell'albumina. *Il Servizio Trasfusionale* 2002; **3**: 5-10.
 - 33) Prinoth O. Servizio Aziendale di Immunoematologia e Trasfusione - Comprensorio Sanitario di Bolzano. Terapia con emocomponenti e plasmaderivati: linee guida ed aspetti medico-legali. January 2007. Available at: [http://www.asbz.it/portal/it/document/IT/direzione/LINEE%20GUIDA%20ALLA%20TRASFUSIONE-ITALIANE%20\(integrale\).pdf](http://www.asbz.it/portal/it/document/IT/direzione/LINEE%20GUIDA%20ALLA%20TRASFUSIONE-ITALIANE%20(integrale).pdf).
 - 34) Pulimood TB, Park GR. Debate: albumin administration should be avoided in the critically ill. *Crit Care* 2000; **4**: 151-5.
 - 35) Alderson P, Schierhout G, Roberts I, Bunn F. Colloids versus crystalloids for fluid resuscitation in critically ill patients. *Cochrane Database Syst Rev* 2000; **4**: CD000567.
 - 36) Bunn F, Alderson P, Hawkins V. Colloid solutions for resuscitation. *Cochrane Database Syst Rev* 2003; **1**: CD001319.
 - 37) Roberts I, Alderson P, Bunn F, et al. Colloids vs crystalloids for fluid resuscitation in critically ill patients. *Cochrane Database Syst Rev* 2004; **4**: CD000567.
 - 38) Perel P, Roberts I. Colloids versus crystalloids for fluid resuscitation in critically ill patients. *Cochrane Database Syst Rev* 2007; **4**: CD000567.
 - 39) Martin GS, Mangialardi RJ, Wheeler AP, et al. Albumin and furosemide therapy in hypoproteinemic patients with acute lung injury. *Crit Care Med* 2002; **30**: 2175-82.
 - 40) Martin GS, Moss M, Wheeler AP, et al. A randomized controlled trial of furosemide with or without albumin in hypoproteinemic patients with acute lung injury. *Crit Care Med* 2005; **33**: 1681-7.
 - 41) Parving HH, Worm AM, Rossing N. Plasma volume, intravascular albumin and its transcapillary escape rate in patients with extensive skin disease. *Br J Dermatol* 1976; **95**: 519-24.
 - 42) Worm AM, Taaning E, Rossing N, et al. Distribution and degradation of albumin in extensive skin disease. *Br J Dermatol* 1981; **104**: 389-96.
 - 43) Riegger LQ, Voepel-Lewis T, Kulik TJ, et al. Albumin versus crystalloid prime solution for cardiopulmonary bypass in young children. *Crit Care Med* 2002; **30**: 2649-54.
 - 44) Russell JA, Navickis RJ, Wilkes MM. Albumin versus crystalloid for pump priming in cardiac surgery: meta-analysis of controlled trials. *J Cardiothorac Vasc Anesth* 2004; **18**: 429-37.
 - 45) Molter GP, Soltesz S, Larsen R, et al. Haemodynamic effects following preoperative hypervolemic haemodilution with hypertonic hyperoncotic colloid solutions in coronary artery bypass graft surgery. *Anaesthetist* 2003; **52**: 905-18.
 - 46) Schroth M, Plank C, Meissner U, et al. Hypertonic-hyperoncotic solutions improve cardiac function in children after open-heart surgery. *Pediatrics* 2006; **118**: 76-84.
 - 47) Johnson PN, Romanelli F, Smith KM, et al. Analysis of morbidity in liver transplant recipients following human albumin supplementation: a retrospective pilot study. *Prog Transplant* 2006; **16**: 197-205.
 - 48) Lasky LC, Finnerty EP, Genis L, Polesky HF. Protein and colloid osmotic pressure changes with albumin and/or saline replacement during plasma exchange. *Transfusion* 1984; **24**: 256-9.
 - 49) Quillen K, Berkman EM. Introduction to therapeutic apheresis. In: McLeod BC, Price TH, Weinstein R, eds. *Apheresis: Principles and Practice*, 2nd ed., Bethesda, MD: AABB Press; 2003. p. 49-69.
 - 50) Crookston K, Simon TL. Physiology of apheresis. In: McLeod BC, Price TH, Weinstein R, eds. *Apheresis: Principles and Practice*, 2nd ed., Bethesda, MD: AABB Press; 2003. p. 71-93.
 - 51) Gentilini P, Casini-Raggi V, Di Fiore G, et al. Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial. *J Hepatol* 1999; **30**: 639-45.
 - 52) Chalasani N, Gorski JC, Horlander JC, et al. Effects of albumin/furosemide mixtures on responses to furosemide in hypoalbuminemic patients. *J Am Soc Nephrol* 2001; **12**: 1010-6.
 - 53) Vizzuti F, Romanelli RG, Casini Raggi V, et al. Diuretic and natriuretic effects of long term albumin infusion in patients with cirrhosis and ascites. A randomized controlled study [abstract]. *J Hepatol* 2001; **34** (Suppl 1): S17.
 - 54) Laffi G, Gentilini P, Romanelli RG, La Villa G. Is the use of albumin of value in the treatment of ascites in cirrhosis? The case in favour. *Dig Liver Dis* 2003; **35**: 660-3.
 - 55) Gines P, Cardenas A, Arroyo V, Rodes J. Management of cirrhosis and ascites. *N Engl J Med* 2004; **350**: 1646-54.
 - 56) Runyon BA; Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD). Management of adult patients with ascites due to cirrhosis. *Hepatology* 2004; **39**: 841-56.

- 57) Gentilini P, Bernardi M, Bolondi L, et al. The rational use of albumin in patients with cirrhosis and ascites. A Delphi study for the attainment of a consensus on prescribing standards. *Dig Liver Dis* 2004; **36**: 539-46.
- 58) Moreau R, Valla DC, Durand-Zaleski I, et al. Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid: a randomised controlled pilot trial. *Liver Int* 2006; **26**: 46-54.
- 59) Romanelli RG, La Villa G, Barletta G, et al. Long-term albumin infusion improves survival in patients with cirrhosis and ascites: an unblinded randomized trial. *World J Gastroenterol* 2006; **12**: 1403-7.
- 60) Gines A, Fernandez-Esparrach G, Monescillo A, et al. Randomized trial comparing albumin, Dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. *Gastroenterology* 1996; **111**: 1002-10.
- 61) Gines P, Tito L, Arroyo V, et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. *Gastroenterology* 1988; **94**: 1493-502.
- 62) Salerno F, Badalamenti S, Lorenzano E, et al. Randomized comparative study of hemagel vs albumin infusion after total paracentesis in cirrhotic patients with refractory ascites. *Hepatology* 1991; **13**: 707-13.
- 63) Fassio E, Terg R, Landeira G, et al. Paracentesis with dextran 70 vs. paracentesis with albumin in cirrhosis with tense ascites. Results of a randomized study. *J Hepatol* 1992; **14**: 310-6.
- 64) Planas R, Gines P, Arroyo V, et al. Dextran-70 vs albumin as plasma expanders in cirrhotic patients with tense ascites treated with total paracentesis. Results of a randomized study. *Gastroenterology* 1990; **99**: 1736-44.
- 65) Gines P, Guevara M, Arroyo V, Rodes J. Hepatorenal syndrome. *Lancet* 2003; **362**: 1819-27.
- 66) Cárdenas A, Arroyo V. Hepatorenal syndrome. *Ann Hepatol* 2003; **2**: 23-9.
- 67) Arroyo V, Terra C, Ginès P. New treatments of hepatorenal syndrome. *Semin Liver Dis* 2006; **26**: 254-64.
- 68) Cárdenas A, Ginès P. Therapy insight: management of hepatorenal syndrome. *Nat Clin Pract Gastroenterol Hepatol* 2006; **3**: 338-48.
- 69) Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. *N Engl J Med* 1999; **341**: 403-9.
- 70) Runyon BA. Albumin infusion for spontaneous bacterial peritonitis. *Lancet*. 1999; **354**: 1838-9.
- 71) Rimola A, Garcia-Tsao G, Navasa M, et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. *J Hepatol* 2000; **32**: 142-53.
- 72) Wong F, Bernardi M, Balk R, et al. Sepsis in cirrhosis: report on the 7th meeting of the International Ascites Club. *Gut* 2005; **54**: 718-25.
- 73) Fernandez J, Monteagudo J, Bargallo X, et al. Randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis. *Hepatology* 2005; **42**: 627-34.
- 74) Wong F. Volume expanders for spontaneous bacterial peritonitis: are we comparing oranges with oranges? *Hepatology* 2005; **42**: 533-5.
- 75) Yoshimura A, Ideura T, Iwasaki S, et al. Aggravation of minimal change nephrotic syndrome by administration of human albumin. *Clin Nephrol* 1992; **37**: 109-14.
- 76) Akcicek F, Yalniz T, Basci A, et al. Diuretic effect of furosemide in patients with nephrotic syndrome: is it potentiated by intravenous albumin? *BMJ* 1995; **310**: 162-3.
- 77) Haller C. Hypoalbuminemia in renal failure: pathogenesis and therapeutic considerations. *Kidney Blood Press Res* 2005; **28**: 307-10.
- 78) Margaron MP, Soni NC. Effects of albumin supplementation on microvascular permeability in septic patients. *J Appl Physiol* 2002; **92**: 2139-45.
- 79) Margaron MP, Soni NC. Changes in serum albumin concentration and volume expanding effects following a bolus of albumin 20% in septic patients. *Br J Anaesth* 2004; **92**: 821-7.
- 80) Emili S, Black NA, Paul RV, et al. A protocol-based treatment for intradialytic hypotension in hospitalized hemodialysis patients. *Am J Kidney Dis* 1999; **33**: 1107-14.
- 81) Knoll GA, Grabowski JA, Dervin GF, O'Rourke K. A randomized, controlled trial of albumin versus saline for the treatment of intradialytic hypotension. *J Am Soc Nephrol* 2004; **15**: 487-92.
- 82) Nakamoto H, Honda N, Mimura T, Suzuki H. Hypoalbuminemia is an important risk factor of hypotension during hemodialysis. *Hemodial Int* 2006; **10** (Suppl 2): S10-5.
- 83) Leon JB, Albert JM, Gilchrist G. Improving albumin levels among hemodialysis patients: a community-based randomized controlled trial. *Am J Kidney Dis* 2006; **48**: 28-36.
- 84) Asplund K. Haemodilution for acute ischaemic stroke. *Cochrane Database Syst Rev* 2002; **4**: CD000103.
- 85) Ben-Chetrit A, Elda-Geva T, Gal M, et al. The questionable use of albumin for the prevention of ovarian hyperstimulation syndrome in an IVF programme: a randomized placebo-controlled trial. *Human Reprod* 2001; **16**: 1880-4.
- 86) Aboulghar M, Evers JH, Al-Inany H. Intra-venous albumin for preventing severe ovarian hyperstimulation syndrome. *Cochrane Database Syst Rev* 2002; **2**: CD001302.
- 87) Bellver J, Muñoz EA, Ballesteros A, et al. Intravenous albumin does not prevent moderate-severe ovarian hyperstimulation syndrome in high-risk IVF patients: a randomized controlled study. *Human Reprod* 2003; **18**: 2283-8.
- 88) Laxenaire MC, Charpentier C, Feldman L. Anaphylactoid reactions to colloid plasma substitutes: incidence, risk factors, mechanisms. A French multicenter prospective study. *Ann Fr Anesth Reanim* 1994; **13**: 301-10.

Immunoglobulins

Introduction

Immunoglobulins (IG) are registered for a limited number of indications¹, but are used much more extensively in clinical practice. Many of the uses do not always appear fully justified by the data in the literature.

Intravenous immunoglobulins (IVIG) are used as replacement therapy in immunodeficiency states and in the treatment of autoimmune diseases and systemic inflammatory disorders.

In Italy preparations of soluble IG have been available for subcutaneous infusion since 2007.

Notions of pharmacokinetics

Following intravenous administration, normal human IG are immediately and completely bioavailable: the peak serum level is dose-related. The IG distribute relatively quickly between the plasma and extravascular fluids; the equilibrium between the intravascular and extravascular compartments is reached after approximately 3-5 days^{2,3}. The initial decrease in serum levels is the result not only of the extravascular redistribution, but also of other factors, including metabolism of denatured molecules and clearance of immune complexes that may have formed after an interaction with an antigen. The half-life of IG is estimated to be about 18-32 days, which is similar to that of endogenous IgG. There is, however, a considerable individual variability that reflects various factors, including the level of IG before the infusion, the peak level after the infusion and the presence of infections or burns.

Preparations of immunoglobulins

IVIG, like all other plasma derivatives, are prepared using pools of human plasma; this leads to significant idiotypic diversity, which guarantees the recipient a greater antibody cover. The preparations of IVIG contain structurally and functionally intact immunoglobulins, with a normal half-life and proportion of the subclasses: 95% of monomeric IgG, small quantities of dimers, variable quantities of IgA and IgM^{2,4-10}. They do not contain high molecular weight immune complexes or contaminants such as vasomotor peptides and endotoxins.

They are prepared from plasma from healthy donors and, furthermore, undergo industrial

processing^{4,5,10}, chemical and physical removal and inactivation of bacteria and viruses.

Mechanism of action

In humoral immunodeficiencies, the IG are administered intravenously to replace those that are lacking because of a deficiency in their production.

Numerous studies have shown that IVIG also have powerful immunomodulatory and anti-inflammatory effects, although the *in vivo* mechanisms of these effects are partly unknown. Various mechanisms have been proposed over time to explain the effects of IVIG in disorders of immune system regulation^{2,7,11-25}:

- interaction of the Fc fragment with specific receptors (FcγR)^{2,7,17,19,25};
- control of the complement pathway and activation of mechanisms inducing solubilisation of circulating immune complexes^{2,7,15,18,25};
- interaction with the idiotype anti-idiotype network^{2,7,17,18,23,25};
- modulation of the production of some cytokines and their antagonists^{2,7,13,17,18,25};
- increased catabolism of IgG^{2,7,17};
- apoptosis of B and T cells through activation of the Fas receptor (apoptosis stimulating fragment - CD95)^{7,14,25};
- blockage of the binding between T cells and superantigens^{2,7,11,25};
- control of autoreactivity and induction of tolerance to self^{2,7,18,25};
- inhibition of the differentiation and maturation of dendritic cells^{2,24,25}.

Indications

Table I, drawn from the *Gazzetta Ufficiale* N. 260 of 6/11/2002¹, provides a summary of the indications and doses recommended for the diseases that are listed^{1,2,7,18,23,25-69}. Table II, on the other hand, presents the clinical conditions for which the routine use of IVIG is not recommended, despite their being reports of the use of this product; the low levels of evidence are due to the lack of studies in sufficiently large series of patients, in turn a consequence of the rarity of the diseases^{2,7,18,25,35,36,44,45,51-58,64,70-96}.

Finally, table III lists the inappropriate indications^{2,7,22,26,36,40,44,45,51,52,54,56,64,71,97-106}.

Replacement therapy

The use of IVIG for the treatment of patients with

Table I – Recognised indications for IVIG (Gazzetta Ufficiale of 06/11/2002, N. 260)¹

Indication	Dose	Frequency of administration
Immunodeficiencies		
Primary immunodeficiency ^{7,18,26-36,46,47}	initial dose: 0.4-0.8 g/kg maintenance: 0.2-0.8 g/kg	every 2-4 weeks to obtain an IgG level of at least 4-6 g/L
Secondary immunodeficiency ^{7,18,26,29,31-45}	0.2-0.4 g/kg	every 3-4 weeks to obtain an IgG level of at least 4-6 g/L
Children with AIDS ^{7,18,33-36,39}	0.2-0.4 g/kg	every 3-4 weeks
Immunomodulation		
ITP or Werlhof's syndrome ^{7,18,25,35,36,44,45,48-50}	0.8-1.0 g/kg or 0.4 g/kg/die	on day 1, possibly repeated a single time within 3 days for 2-5 days
Guillain-Barré syndrome ^{2,7,18,23,25,35,42-44,46,47,51-64}	0.4 g/kg/die	for 3-7 days
Kawasaki's disease ^{7,18,25,26,35,36,65-69}	1.6-2 g/kg or 2 g/kg	in several doses over 2-5 days in association with ASA in a single dose in association with ASA
Allogeneic bone marrow transplantation		
Treatment and prophylaxis of infections and GvHD ^{7,18,25,35,36,44,45}	0.5 g/kg	every week from day -7 until 3 months after the transplant
Persistent deficit of the production of antibodies ^{7,35,36,44,45}	0.5 g/kg	every month until normalisation of the levels of antibodies

Table II - Clinical conditions for which the routine use of IVIG is not recommended, although their use has been reported

Clinical conditions	Indications and dose	GoR
Haematology		
Alloimmune neonatal thrombocytopenia ^{7,35,36,44,45,71,73,75}	IVIG are recommended in symptomatic neonates, at high risk of intracranial bleeding, if other strategies have been unsuccessful, not tolerated or contraindicated. IVIG can be used prior to delivery in high-risk mothers, with a history of alloimmune neonatal thrombocytopenia and foetal or neonatal thrombocytopenia. 1g/kg per week (to the mother).	2C
Autoimmune haemolytic anaemia (AEA) ^{7,25,35,36,44,45,70}	IVIG can play a role in patients with AEA due to warm antibodies (Ab) not responsive to cortico-steroids or splenectomy, or in those in whom the abovementioned treatments are contraindicated. 0.4 g/kg/die for 5 days.	2C
Haemolytic disease of the newborn (HDN) ^{7,36,44,45,71,72}	IVIG are recommended in neonates with severe HDN (0.5-1g/kg/die for three doses), if other therapeutic strategies are not feasible. The IVIG may be given to the mother before delivery if other strategies have been unsuccessful, not tolerated or contraindicated.	2C
Immune-mediated neutropenia ^{7,44,45}	IVIG may have a role in patients in whom other strategies have been unsuccessful, not tolerated or contraindicated.	2C
Post-transfusion purpura ^{7,36,44,45,73,74}	IVIG may be considered in severely affected patients.	2C

follows

Clinical conditions	Indications and dose	GoR
Pure red cell aplasia ^{44,45,96}	IVIg can be used in patients with documented Parvovirus B19 infection and severe anaemia. 0.4 g/kg every 28 days.	2C
Refractoriness to platelet transfusion ^{7,73}	IVIg may have a role in patients in whom other strategies have been unsuccessful, not tolerated or contraindicated.	2C
Infectious diseases		
CMV prophylaxis in solid organ transplants ^{7,18}	IVIg can be used in CMV-negative recipients of CMV-positive organs. 0.4 g/kg every 28 days.	2C+
Neurology		
Acute disseminated encephalomyelitis ^{44,64}	IVIg can be considered if first-line therapy (high-dose steroids) is ineffective or contraindicated. 2g/kg in 2 days for children or in 2-5 days for adults.	2B
Chronic inflammatory demyelinating polyneuropathy ^{2,7,18,25,35,36,44,51-58,64,79-84}	IVIg are recommended as an equivalent choice to therapeutic plasmapheresis in the acute phase in children and adults. Their use in chronic treatment is currently suggested only from observational studies. 0.4 g/kg/die for 5 days	1A 2C
Intractable childhood epilepsy ^{44,51,64}	IVIg can play a role in some syndromes (e.g. West,Lennox-Gastaut) as a last strategy, particularly in patients who could be candidates for surgical resection.	2C
Lambert-Eaton syndrome ^{2,36,44,51,52,55,56,64,86}	IVIg can be considered in patients with a severe syndrome, if other strategies have been unsuccessful, not tolerated or contraindicated. 0.4 g/kg/die for 5 days.	2C+
Multifocal motor neuropathy ^{2,7,18,25,36,44,51-58,64,77,78}	IVIg can be considered in patients who have a progressive and symptomatic multifocal neuropathy, diagnosed on the basis of electrophysiological findings that exclude other possible conditions that do not respond to this treatment. 0.4 g/kg/die for 5 days.	2C+
Multiple sclerosis ^{2,7,18,25,35,44,51-53,55,64,85}	IVIg can be considered in patients with moderate or severe manifestations of multiple sclerosis in recurrence-remission, in whom other strategies have been unsuccessful, not tolerated or contraindicated.	2C
Myasthenia gravis ^{2,7,35,44,51-53,55,56,64,76}	IVIg can be considered in patients with myasthenic crises (0.4 g/kg/die for 5 days or 2g/kg for 2 days). Maintenance treatment is still experimental.	2C+
Stiff-person syndrome ^{2,7,18,25,36,44,52,55,56,64,87,88}	IVIg were found to be effective in one randomised clinical study (14 patients); they may have a role if GABA-ergic drugs have been ineffective or contra-indicated. 2 g/kg/month.	2B
Rheumatology		
Dermatomyosites, Polymyosites ^{2,7,18,25,36,44,51-53,55,56,64,89}	IVIg can be used in patients with active, severe disease in whom other strategies have been unsuccessful, not tolerated or contraindicated. 0.4 g/kg/die for 5 days.	2C+
Systemic lupus erythematosus (SLE) ^{7,25,53}	IVIg can be used in patients with active, severe SLE in whom other strategies have been unsuccessful, not tolerated or contraindicated.	2C+
Systemic vasculitides ^{7,36}	IVIg can be used in patients with active, severe disease, particularly in those with ANCA-positive vasculitis or other systemic vasculitis, in whom other strategies have been unsuccessful, not tolerated or contraindicated.	2C+
Renal transplantation		
Pre-transplant desensitisation ^{7,35,90-95}	IVIg can be used (also together with plasmapheresis) in patients with high pre-transplant levels of anti-HLA Ab as a desensitising strategy.	2B

GoR: Grade of Recommendation

Table III –Inappropriate indications for the use of IVIG

Clinical conditions	GoR
Haematology	
Acquired inhibitors of FVIII ^{44,45}	2C
Acquired von Willebrand's disease ^{44,45}	2C
Aplastic anaemia ^{44,45}	2C
Diamond-Blackfan anaemia ^{22,26}	2C
TTP and uraemic-haemolytic syndrome ^{44,45}	2C
Infectious diseases	
Burns (prophylaxis from infections) ^{22,26}	2C
HIV infection (adult) ^{22,26}	2C
Surgery and/or trauma (prophylaxis) ⁷	1A
Rheumatology	
Inclusion body myositis ^{22,26}	1A
Rheumatoid arthritis (juvenile and adult) ^{7,105}	1A
Miscellaneous	
Acute cardiomyopathy ^{22,26,99}	2C
Acute idiopathic dysautonomia ^{22,26}	2C
Acute lymphoblastic leukaemia ^{22,26}	1A
Acute renal failure ^{22,26}	1A
Adrenoleucodystrophy ^{44,64}	2C
Amyotrophic lateral sclerosis ^{44,51,64}	2C
Autism ^{7,44,64}	2C
Autoimmune bullous dermatoses ^{22,26,36}	2C
Autoimmune childhood neuropsychiatric disorders associated with streptococcal infections ^{44,64}	2C
Behçet's disease ^{22,26}	2C
Bronchial asthma ^{7,98}	1A
Chronic fatigue syndrome ^{22,26}	2C
Congenital cardiac arrest ^{22,26}	1A
Cystic fibrosis ^{22,26}	1A
Diabetes mellitus ⁷	2C
Diabetic neuropathy ^{44,64}	2C
Endotoxaemia ^{22,26}	2C
Euthyroid ophthalmopathy ^{22,26}	2C
Haemolytic transfusion reaction ^{44,45}	2C
Haemophagocytic syndrome ^{22,26}	2C
HTLV-1-associated myelopathy ^{22,26}	2C
Inclusion body myositis ^{44,56,64}	2C
Inflammatory bowel diseases (Crohn's disease, ulcerative colitis) ⁷	2C
Lower motor neurone syndrome ^{22,26}	2C
Lyell's syndrome ^{7,102}	2C
Lyme radiculoneuritis ^{22,26}	2C
Nephritic syndrome ^{22,26}	2C
Nephrotic syndrome ^{22,26}	1A
Non-immunological thrombocytopenia ^{22,26,44,45}	2C
Opsoclonus-myoelonus ^{44,64}	2C
Paraneoplastic cerebellar degeneration ^{22,26,51}	2C
Paraproteinaemic neuropathy ^{44,51,52,56,64,101}	2C
Parvovirus infection (in general) ^{22,26}	2C
POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, protein M, skin alterations) ^{22,26,44,51,64}	2C
Polyneuropathy in the critically ill patient ^{44,64}	2C
Progressive lumbo-sacral plexopathy ^{22,26}	2C
Rasmussen's syndrome ^{22,26,44,51}	2C
Recurrent abortions ^{7,71,97}	1A
Recurrent otitis media ^{22,26}	2C
Reiter's syndrome ^{22,26}	2C
Streptococcal septic shock ^{22,26,40}	2C
Uveitis ^{22,26}	2C
Viral myocarditis (presumed) ¹⁰⁰	2C+
Vogt-Koyanagi-Harada syndrome ^{22,26}	2C

GoR: Grade of Recommendation

primary or secondary antibody deficiencies was authorised in the USA in 1981, since when it has been possible to exploit this product, by then purified of the high molecular weight aggregates responsible for severe reactions, using the Cohn-Oncley separation technique⁴.

Compared to the previous treatment based on intramuscular IG, the use of IVIG enabled higher doses of IG to be administered, thus permitting normalisation of blood levels. The aim of treatment is to maintain serum levels (before the next infusion) of IgG > 5 g/dL; the clinical condition of the patient must, of course, always be evaluated³³.

Reaching these levels leads to the patient having fewer febrile episodes and, in general, reductions in the number of recurrent infections, days spent in hospital and time on antibiotic treatment, an improvement in indices of respiratory function and, in paediatric patients, an increase in body weight, which is an indicator of an improved quality of life.

Primary deficiencies

- Humoural immunodeficiencies^{22,26}:
 - a) X-linked agammaglobulinaemia;
 - b) common variable immunodeficiency;
 - c) immunodeficiency with hyper-IgM;
 - d) transient childhood hypogammaglobulinaemia (sometimes);
 - e) deficiencies of IgG subclasses (sometimes with or without IgA deficiencies).
- Combined immunodeficiencies^{22,26}:
 - a) all types of severe combined immunodeficiencies;
 - b) Wiskott-Aldrich syndrome;
 - c) ataxia-telangiectasia;
 - d) short-limbed dwarfism;
 - e) X-linked lymphoproliferative disease.

Treatment with IVIG is indicated if the level of IgG is below 5 g/L. It takes 3 to 6 months after the start of treatment for a balance to be reached. The recommended starting dose is 0.4-0.8 g/kg of body weight; this should be followed by 0.2-0.8 g/kg every 2-4 weeks, in order to achieve minimum IgG levels > 5 g/dL (*Grade of recommendation: 1A*)^{1,7,18,26-36}.

Secondary deficiencies

- a) In lymphoproliferative diseases with antibody deficits (multiple myeloma, chronic lymphocytic

leukaemia, non-Hodgkin's lymphoma) the use of IVIG, to maintain plasma IG levels > 4-6 g/L, is indicated for patients with a documented deficiency in antibodies and recurrent infections; the dose is 0.2-0.4 g/kg every 4 weeks (*Grade of recommendation: IA*)^{1,7,18,26,29,31-45}.

- b) Acquired immunodeficiency syndrome in childhood: IVIG can be used in HIV-positive children with hypogammaglobulinaemia to prevent opportunistic infections, in cases of recurrent bacterial infections and/or ineffective antibiotic and antiretroviral therapy; the dose is 0.2-0.4 g/kg every 4 weeks (*Grade of recommendation: 2C+*)^{7,18,33-36,39,46,47}.
- c) Allogeneic bone marrow transplantation: IVIG can be used in the treatment of infections and the prophylaxis of GvHD, at the dose of 0.5 g/kg every week from 7 days before the transplant until 3 months after it. In the case of a persistent deficit in antibody production, the dose is 0.5 g/kg every 4 weeks until the levels of IgG normalise (*Grade of recommendation: 2C*)^{1,7,18,25,35,36,44,45}.
- d) Prematurity: prophylaxis with IVIG may play a role in the management of low birth weight neonates (< 1,500 g) or in those with severe infections; the dose is 0.4-0.7 g/kg in 1-7 administrations^{22,26}.

Immunomodulation

For some years IVIG have also been used in immunomodulation therapy. High doses of IVIG have immunosuppressive and anti-inflammatory effects and have, therefore, been used in the treatment of autoimmune and/or inflammatory diseases, as well as in haematological, rheumatological and neurological conditions.

The only indications for which there is recognised to be high levels of evidence are: ITP, Kawasaki's disease and Guillain-Barré syndrome.

- e) In ITP, IVIG are, in any case, used after other pharmacological treatments have failed; the exceptions to this are acute episodes associated with bleeding or cases in which surgery is considered necessary; in these situations the recommended dose is 0.8-1 g/kg on the first day, which can be repeated within 3 days, or 0.4 g/kg/die for 2-5 days (*Grade of recommendation: IA*)^{7,18,25,35,36,44,45,48-50}.
- f) The recommended dose in Kawasaki's disease is

1.6-2 g/kg, in divided administrations over 2-5 days or 2 g/kg in a single administration; this latter method of administration has been shown to be more effective in preventing aneurysmal complications of the coronary arteries. Concomitant treatment with acetylsalicylic acid (ASA) is recommended (*Grade of recommendation: IA*)^{7,18,25,26,35,36,65-69}.

- g) The dose in Guillain-Barré syndrome is 0.4 g/kg/die for 3-7 days (*Grade of recommendation: IA*)^{2,7,18,23,25,35,42-44,51-64}.

IVIG are used in numerous other conditions; nevertheless, their routine use is not recommended and they should be employed only in particular situations or as an alternative to other therapeutic measures. Table II lists the diseases for which the use of IVIG has been suggested based on their mechanism of action, results of uncontrolled, single clinical trials or authoritative opinion drawn from clinical experience, descriptive studies or single case reports.

Monitoring indices for clinical auditing

Administration of IVIG treatment in the following conditions:

- replacement therapy when IG > 6 g/L;
- immunomodulation in diseases for which there are not recognised indications.

Side effects and adverse reactions

Side effects of variable severity occur in 1-15% of treated patients, but are usually of limited clinical importance. They include headache, shivers, hyperthermia, fever, allergic reactions, nausea, vomiting, joint pains, and hypotension to the point of anaphylactic shock, even in patients who have not shown signs of hypersensitivity to previous administrations^{2,5,7,107}. Although the aetiology remains uncertain, it seems that aggregates of IgG, IgG-dimers and activation of the complement pathway may be involved. The aggregates are able to activate complement even in the absence of the antigen⁷.

Patients with an antibody deficiency more frequently have reactions, including anaphylactic ones; slow infusion seems to lower the risks. Most of these reactions resolve with temporary interruption of the infusion or a slowing of its rate of administration, or can be prevented by giving ASA, paracetamol or anti-histamines before the treatment and/or hydrocortisone during it¹⁰⁷. Severe anaphylactic

reactions have occurred in patients with IgA deficiency. Although the content of IgA in IVIG preparations is modest and, in any case, varies between products, small amounts can cause fatal reactions, especially in patients with anti-IgA immunoglobulin E^{2,7}.

Thromboembolic events have been reported, particularly in elderly patients, in patients with previous cerebral or cardiac ischaemia, in overweight patients, those who are markedly hypovolaemic and in immobilised subjects¹⁰⁸⁻¹¹⁰.

Rare cases of reversible aseptic meningitis have also been observed in patients with neurological and neuromuscular diseases treated with high doses of IVIG¹¹¹. The symptoms appear within 6-24 hours of the end of the infusion and disappear without sequelae in 3-5 days.

Increases in creatinine and/or renal failure, particularly acute, have been observed rarely in elderly, diabetic, poorly hydrated patients, with pre-existing renal disease or who are taking nephrotoxic drugs. These problems are probably related to damage caused to the renal tubules by the saccharose included in various preparations as a stabiliser^{112,113}.

As far as concerns the possibility of transmitting infectious agents with these plasma-derivatives, there is a potential risk of transmission of spongiform encephalopathies (Creutzfeld-Jacob disease, Gerstmann Straussler-Scheinker disease and fatal familial insomnia), since the prions responsible for these diseases are resistant to standard methods of inactivation. Furthermore, solvent/detergent inactivation is ineffective against viruses that do not have a lipid envelope, such as HAV and parvovirus B19¹¹⁴.

Precautions and recommendations

It is recommended that the details of the product infused, including the batch number, are recorded in the clinical records.

Side effects can be partly prevented by injecting the product slowly at the beginning and monitoring the patient for the appearance of any symptoms. Monitoring should be particularly careful for patients who have never received IVIG, those being given a different preparation from a previous one and when a long period has passed between one infusion and another; in such cases the patients should be monitored during the infusion and for the first hour after its

completion. All other patients should be observed for at least 20 minutes after the product has been administered.

All patients must be well hydrated prior to the infusion and production of urine and levels of serum creatinine should be monitored. Furthermore, it should be ascertained whether the patient has diabetes or pre-existing renal failure, is taking loop diuretics or nephrotoxic drugs; in these patients preparations containing saccharose, used as a stabiliser, should be avoided.

References

- 1) Gazzetta Ufficiale della Repubblica Italiana –Serie Generale N. 260 del 06/11/2002. Ministero della Sanità –Decreto 2/10/2002. Specialità medicinali contenenti immunoglobuline umane normali per uso endovenoso.
- 2) Dalakas MC. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular disease: evidence-based indications and safety profile. *Pharmacol Ther* 2004; **102**: 177-93.
- 3) Pirofsky B, Campbell SM, Montanaro A. Individual patient variations in the kinetics of intravenous immune globulin administration. *J Clin Immunol* 1982; **2** (Suppl 2): 7S-14S.
- 4) Cohn EJ, Gurd FRN, Surgenor DM, et al. A system for the separation of the components of human blood: quantitative procedures for the separation of the protein components of human plasma. *J Am Chem Soc* 1950; **72**: 465.
- 5) Farrugia A, Poulis P. Intravenous immunoglobulin: regulatory perspectives on use and supply. *Transfus Med* 2001; **11**: 63-74.
- 6) Miller JL, Peteway SR Jr, Lee DC. Ensuring the pathogen safety of intravenous immunoglobulin and other human plasma-derived therapeutic proteins. *J Allergy Clin Immunol* 2001; **108** (Suppl 4): S91-4.
- 7) Knezevic-Maramica I, Kruskall MS. Intravenous immune globulins: an update for clinicians. *Transfusion* 2003; **43**: 1460-80.
- 8) Gazzetta Ufficiale della Repubblica Italiana –Serie Generale N. 85 del 13/04/05. Decreto Legislativo 3 Marzo 2005. Caratteristiche e modalità per la donazione di sangue e di emocomponenti.
- 9) Council of Europe. *Guide to the preparation, use and quality assurance of blood components. Recommendation No R (95) 15 on the Preparation, Use and Quality Assurance of Blood Components*, 14th ed, Strasbourg, Council of Europe Press; 2008.
- 10) Burnouf T. Modern plasma fractionation. *Transfus Med Rev* 2007; **21**: 101-17.
- 11) Takei S, Arora YK, Walker AM. Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens. *J Clin Invest* 1993; **91**: 602-7.
- 12) Lam L, Whitsett CF, McNicholl JM, et al.

- Immunologically active proteins in intravenous immunoglobulin. *Lancet* 1993; **342**: 678.
- 13) Aukrust P, Frøland SS, Liabakk NB, et al. Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. *Blood* 1994; **84**: 2136-43.
 - 14) Prasad NK, Papoff G, Zeuner A, et al. Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway. *J Immunol* 1998; **161**: 3781-90.
 - 15) Mollnes TE, Hogasen K, De Carolis C, et al. High-dose intravenous immunoglobulin treatment activates complement in vivo. *Scand J Immunol* 1998; **48**: 312-7.
 - 16) Spellberg B. Mechanism of intravenous immune globulin therapy. *N Engl J Med* 1999; **341**: 57-8.
 - 17) Yu Z, Lennon VA. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. *N Engl J Med* 1999; **340**: 227-8.
 - 18) Sacher RA, et al. Intravenous immunoglobulin consensus statement. *J Allergy Clin Immunol* 2001; **108**: S139-46.
 - 19) Ott VL, Fong DC, Cambier JC. FC gamma RIIB as a potential molecular target for intravenous gamma globulin therapy. *J Allergy Clin Immunol* 2001; **108** (Suppl 4): S95-8.
 - 20) Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. *Science* 2001; **291**: 484-6.
 - 21) Aukrust P, Gullestad L, Lappégard KT, et al. Complement activation in patients with congestive heart failure: effect of high-dose intravenous immunoglobulin treatment. *Circulation* 2001; **104**: 1494-500.
 - 22) Rinaldi S, Prinoto O. Proposta di linee guida per l'uso clinico delle immunoglobuline umane per somministrazione endovenosa (IVIG). *Il Servizio Trasfusionale*, 2002, **3**: 12-9.
 - 23) Buchwald B, Ahangari R, Weishaupt A, Toyka KV. Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barré syndrome. *Ann Neurol* 2002; **52**: 673-80.
 - 24) Bayry J, Lacroix-Desmazes S, Carbonneil C, et al. Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. *Blood* 2003; **101**: 758-65.
 - 25) Ephrem A, Misra N, Hasan G, et al. Immunomodulation of autoimmune and inflammatory disease with intravenous immunoglobulin. *Clin Exp Med* 2005; **5**: 135-40.
 - 26) Prinoto O. Servizio Aziendale di Immunoematologia e Trasfusione - Comprensorio Sanitario di Bolzano. Terapia con emocomponenti e plasmaderivati: linee guida ed aspetti medico-legali. Gennaio 2007. Available at: [http://www.asbz.it/portal/it/document/IT/direzione/LINEE%20GUIDA%20ALLA%20TRASFUSIONE-ITALIANE%20\(integrale\).pdf](http://www.asbz.it/portal/it/document/IT/direzione/LINEE%20GUIDA%20ALLA%20TRASFUSIONE-ITALIANE%20(integrale).pdf).
 - 27) Barandun S, Kistler P, Jeunet F, Isliker H. Intravenous administration of human gamma-globulin. *Vox Sang* 1962; **7**: 157-74.
 - 28) Oxelius VA. Chronic infections in a family with hereditary deficiency of IgG2 and IgG4. *Clin Exp Immunol* 1974; **17**: 19-27.
 - 29) Nolte MT, Pirofsky B, Gerritz GA, Gloding B. Intravenous immunoglobulin therapy for antibody deficiency. *Clin Exp Immunol* 1979; **36**: 237-42.
 - 30) Buckley RH. Long term use of intravenous immune globulin in patients with primary immunodeficiency diseases: inadequacy of current dosage practices and approaches to the problem. *J Clin Immunol* 1982; **2** (Suppl 2): 15S-21S.
 - 31) Ochs HD, Fischer SH, Wedgwood RJ. Modified immune globulin: its use in the prophylactic treatment of patients with immune deficiency. *J Clin Immunol* 1982; **2** (Suppl 2): 22S-30S.
 - 32) Pirofsky B. Intravenous immunoglobulin therapy in hypogammaglobulinemia. A review. *Am J Med* 1984; **76**: 53-60.
 - 33) Stiehm ER. Human intravenous immunoglobulin in primary and secondary antibody deficiencies. *Pediatr Infect Dis J* 1997; **16**: 696-707.
 - 34) Stiehm ER. Immune globulin therapy. In: Mintz PD, editor. *Transfusion therapy: clinical principles and practice*, Bethesda, MD: AABB Press, 1999.
 - 35) Darabi K, Abdel-Wahab O, Dzik WH. Current usage of intravenous immune globulin and the rationale behind it: the Massachusetts General Hospital data and a review of the literature. *Transfusion* 2006; **46**: 741-53.
 - 36) Looney RJ, Huggins J. Use of intravenous immunoglobulin G (IVIG). *Best Pract Res Clin Haematol* 2006; **19**: 3-25.
 - 37) Frickhofen N, Abkowitz JL, Safford M, et al. Persistent B19 parvovirus infection in patients infected with human immunodeficiency virus type 1 (HIV-1): a treatable cause of anemia in AIDS. *Ann Intern Med* 1990; **113**: 926-33.
 - 38) Douzinas EE, Pitaridis MT, Louris G, et al. Prevention of infection in multiple trauma patients by high-dose intravenous immunoglobulins. *Crit Care Med* 2000; **28**: 8-15.
 - 39) Kaplan JE, Masur H, Holmes KK. Guidelines for preventing opportunistic infections among HIV-infected persons—2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. Available at: <http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5108a1.htm>.
 - 40) Alejandra MM, Lansang MA, Dans LF, Mantaring JBV. Intravenous immunoglobulin for treating sepsis and septic shock. *Cochrane Database Syst Rev* 2002; **1**: CD001090.
 - 41) Ohlsson A, Lacy JB. Intravenous immunoglobulin for preventing infection in preterm and/or low-birth-weight infants. *Cochrane Database Syst Rev* 2004; **1**: CD000361.
 - 42) Gelfand EW. Antibody-directed therapy: past, present and future. *J Allergy Clin Immunol* 2001; **108** (Suppl 4): S111-6.
 - 43) Hume HA, Anderson DR. Guidelines for the use of intravenous immune globulin for hematologic and neurologic conditions. *Transfus Med Rev* 2007;

- 21 (Suppl 1): S1-2.
- 44) Robinson P, Anderson D, Brouwers M, et al; IVIG Hematology and Neurology Expert Panels. Evidence-based guidelines on the use of intravenous immune globulin for hematologic and neurologic conditions. *Transfus Med Rev* 2007; **21** (Suppl 1): S3-8.
 - 45) Anderson D, Ali K, Blanchette V, et al. Guidelines on the use of intravenous immune globulin for hematologic conditions. *Transfus Med Rev* 2007; **21** (Suppl 1): S9-56.
 - 46) Provan D, Nokes TJC, Agrawal S, et al. Clinical guidelines for the use of intravenous immunoglobulin. Available at: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_080790.
 - 47) Australian Health Ministers' Conference. Criteria for the clinical use of intravenous immunoglobulin in Australia. Available at: <http://www.nba.gov.au/ivig/pdf/criteria.pdf>.
 - 48) Blanchette V, Imbach P, Andrew M, et al. Randomised trial of intravenous immunoglobulin G, intravenous anti-D and oral prednisone in childhood acute immune thrombocytopenic purpura. *Lancet* 1994; **344**: 703-7.
 - 49) Ancona KG, Parker RI, Atlas MP, Prakash D. Randomized trial of high-dose methylprednisolone versus intravenous immunoglobulin for the treatment of acute idiopathic thrombocytopenic purpura in children. *J Pediatr Hematol Oncol* 2002; **24**: 540-4.
 - 50) Godeau B, Chevret S, Varet B, et al. Intravenous immunoglobulin or high-dose methylprednisolone with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multicentre trial. *Lancet* 2002; **359**: 23-9.
 - 51) Latov N, Chaudhry V, Koski CL, et al. Use of intravenous gamma globulins in neuroimmunologic diseases. *J Allergy Clin Immunol* 2001; **108** (Suppl 4): S126-32.
 - 52) Gold R, Stangel M, Dalakas MC. Drug insight: the use of intravenous immunoglobulin in neurology: therapeutic considerations and practical issues. *Nat Clin Pract Neurol* 2007; **3**: 36-44.
 - 53) Gürçan HM, Ahmed AR. Efficacy of various intravenous immunoglobulin therapy protocols in autoimmune and chronic inflammatory disorders. *Ann Pharmacother* 2007; **41**: 812-23.
 - 54) Czaplinski A, Steck AJ. Immune mediated neuropathies: an update on therapeutic strategies. *J Neurol* 2004; **251**: 127-37.
 - 55) Dalakas MC. Intravenous immunoglobulin in autoimmune neuromuscular diseases. *JAMA* 2004; **291**: 2367-75.
 - 56) Fergusson D, Hutton B, Sharma M, et al. Use of intravenous immunoglobulin for treatment of neurologic conditions: a systematic review. *Transfusion* 2005; **45**: 1640-57.
 - 57) Nobile-Orazio E. Treatment of dys-immune neuropathies. *J Neurol* 2005; **252**: 385-95.
 - 58) Nobile-Orazio E, Terenghi F. IVIg in idiopathic autoimmune neuropathies: analysis in the light of the latest results. *J Neurol* 2005; **252** (Suppl 1): I7-13.
 - 59) Koski CL. Initial and long-term management of autoimmune neuropathies. *CNS Drugs* 2005; **19**: 1033-48.
 - 60) Hughes RAC, Swan AV, Cornblath DR, Hartung HP; Plasma exchange/Sandoglobulin Guillain-Barré syndrome trial group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. *Lancet* 1997; **349**: 225-30.
 - 61) Raphael JC, Chevret S, Hughes RS, Annane D. Plasma exchange for Guillain-Barré syndrome. *Cochrane Database Syst Rev* 2002; **2**: CD001798.
 - 62) Hughes RA, Raphaël JC, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. *Cochrane Database Syst Rev* 2006; **1**: CD002063.
 - 63) Hughes RA, Swan AV, Raphael JC, et al. Immunotherapy for Guillain-Barré syndrome: a systematic review. *Brain* 2007; **130**: 2245-57.
 - 64) Feasby T, Banwell B, Benstead T, et al. Guidelines on the use of intravenous immune globulin for neurologic conditions. *Transfus Med Rev* 2007; **21** (Suppl 1): S57-107.
 - 65) Terai M, Shulman ST. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose, but independent of salicylate dose. *J Pediatr* 1997; **131**: 888-93.
 - 66) Williams RV, Minich LL, Tani LY. Pharmacological therapy for patients with Kawasaki disease. *Paediatr Drugs* 2001; **3**: 649-60.
 - 67) Gedalia A. Kawasaki disease: an update. *Curr Rheumatol Rep* 2002; **4**: 25-9.
 - 68) Lang B. Controversies in the management of Kawasaki disease. *Clin Rheumatol* 2002; **16**: 427-42.
 - 69) Oates-Whitehead RM, Baumer JH, Haine L, et al. Intravenous immunoglobulin for the treatment of Kawasaki disease in children. *Cochrane Database Syst Rev* 2003; **4**: CD004000.
 - 70) Petz LD. Treatment of autoimmune hemolytic anemias. *Curr Opin Hematol* 2001; **8**: 411-6.
 - 71) Branch DW, Porter TF, Paidas MJ, et al. Obstetric uses of intravenous immunoglobulin: successes, failures and promises. *J Allergy Clin Immunol* 2001; **108** (Suppl 4): S133-8.
 - 72) Alcock GS, Liley H. Immunoglobulin infusion for isoimmune haemolytic jaundice in neonate. *Cochrane Database Syst Rev* 2002; **3**: CD003313.
 - 73) British Committee for Standards in Haematology. Guidelines for the use of platelet transfusions. *Br J Haematol* 2003; **122**: 10-23.
 - 74) Practice Guidelines for Blood Transfusion: A Compilation from Recent Peer-Reviewed Literature. American Red Cross 2002. Available at: http://chapters.redcross.org/br/indianaoh/hospitals/transfusion_guidelines.htm.re.
 - 75) Rayment R, Brunskill SJ, Stanworth S, et al. Antenatal interventions for fetomaternal alloimmune thrombocytopenia. *Cochrane Database Syst Rev* 2005; **1**: CD004226.
 - 76) Gajdos P, Chevret S, Toyka K. Intravenous

- immunoglobulin for myasthenia gravis. *Cochrane Database Syst Rev* 2006; **2**: CD002277.
- 77) Van Schaik IN, van den Berg LH, de Haan R, Vermeulen M. Intravenous immunoglobulin for multifocal motor neuropathy. *Cochrane Database Syst Rev* 2005; **2**: CD 004429.
- 78) Umapathi T, Hughes RAC, Nobile-Orazio E, Leger JM. Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy. *Cochrane Database Syst Rev* 2005; **3**: CD003217.
- 79) van Doorn PA. Treatment of patients with chronic inflammatory demyelinating polyneuropathy. *Rev Neurol (Paris)* 1996; **152**: 383-6.
- 80) Hahn AF. Treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulin. *Neurology* 1998; **51** (Suppl 5): S16-21.
- 81) van Schaik IN, Winer JB, de Haan R, Vermeulen M. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. *Cochrane Database Syst Rev* 2002; **2**: CD001797.
- 82) Hughes RA. Systematic reviews of treatment for chronic inflammatory demyelinating neuropathy. *Rev Neurol (Paris)* 2002; **158** (12 Pt 2): S32-6.
- 83) Ropper AH. Current treatments for CIDP. *Neurology* 2003; **60** (Suppl 3): S16-22.
- 84) Kuntzer T. Treatment options for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). *Rev Neurol (Paris)* 2006; **162**: 539-43.
- 85) Hommes OR, Sorensen PS, Fazekas F, et al. Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. *Lancet* 2004; **364**: 1149-56.
- 86) Maddison P, Newsom-Davis J. Treatment for Lambert-Eaton myasthenic syndrome. *Cochrane Database Syst Rev* 2005; **2**: CD003279.
- 87) Dalakas MC. The role of IVIg in the treatment of patients with stiff person syndrome and other neurological diseases associated with anti-GAD antibodies. *J Neurol* 2005; **252** (Suppl 1): I19-25.
- 88) Dalakas MC, Fujii M, Li M, et al. High-dose intravenous immune globulin for stiff-person syndrome. *N Engl J Med* 2001; **345**: 1870-6.
- 89) Choy EHS, Hoogendijk JE, Lecky B, Winer JB. Immunosuppressant and immunomodulatory treatments for dermatomyositis and polymyositis. *Cochrane Database Syst Rev* 2005; **3**: CD003643.
- 90) Montgomery RA, Zachary AA, Racusen LC, et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into crossmatch-positive recipients. *Transplantation* 2000; **70**: 887-95.
- 91) Jordan SC. Management of the highly HLA-sensitized patient. A novel role for intravenous gammaglobulin [editorial]. *Am J Transplant* 2002; **2**: 691-2.
- 92) Jordan S, Cunningham-Rundles C, McEwan R. Utility of intravenous immune globulin in kidney transplantation: efficacy, safety, and cost implication. *Am J Transplant* 2003; **3**: 653-64.
- 93) Jordan CS, Tyan D, Stablein D, et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. *J Am Soc Nephrol* 2004; **15**: 3256-62.
- 94) Jordan SC, Vo AA, Toyoda M, Tyan D. Intravenous gammaglobulin (IVIg): a novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients. *Am J Transplant* 2006; **6**: 459-66.
- 95) Beimler JH, Susal C, Zeier M. Desensitization strategies enabling successful renal transplantation in highly sensitized patients. *Clin Transplant* 2006; **20** (Suppl 17): 7-12.
- 96) Moudgil A, Shidban H, Nast CC, et al. Parvovirus B19 infection-related complications in renal transplant recipients: treatment with intravenous immunoglobulin. *Transplantation* 1997; **64**: 1847-50.
- 97) Porter TF, La Coursiere Y, Scott JR. Immunotherapy for recurrent miscarriage. *Cochrane Database Syst Rev* 2006; **2**: CD000112.
- 98) Kishiyama JL, Valacer D, Cunningham-Rundles C, et al. A multicenter, randomized, double-blind, placebo-controlled trial of high-dose intravenous immunoglobulin for oral corticosteroid-dependent asthma. *Clin Immunol* 1999; **91**: 126-33.
- 99) Cilliers AM, Manyemba J, Saloojee H. Anti-inflammatory treatment for carditis in acute rheumatic fever. *Cochrane Database Syst Rev* 2003; **2**: CD003176.
- 100) Robinson J, Hartling L, Vandermeer B, et al. Intravenous immunoglobulin for presumed viral myocarditis in children and adults. *Cochrane Database Syst Rev* 2005; **1**: CD004370.
- 101) Lunn MPT, Nobile-Orazio E. Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies. *Cochrane Database Syst Rev* 2006; **2**: CD0002827.
- 102) Yip LW, Thong BY, Tan AW, et al. High-dose intravenous immunoglobulin in the treatment of toxic epidermal necrolysis: a study of ocular benefit. *Eye* 2005; **19**: 846-53.
- 103) Paul C, Lahfa M, Bachelez H, et al. A randomised controlled evaluator-blinded trial of intravenous immunoglobulin in adult with severe atopic dermatitis. *Br J Dermatol* 2002; **147**: 518-22.
- 104) Fuller H, Del Mar C. Immunoglobulin treatment for respiratory syncytial virus infection. *Cochrane Database Syst Rev* 2006; **4**: CD004883.
- 105) Orellana JC, Pogonza RE, Lopez-Olivo MA, et al. Intravenous immunoglobulin for juvenile idiopathic arthritis (Protocol). *Cochrane Database Syst Rev* 2006; **4**: CD006191.
- 106) Overell JR, Hsieh ST, Odaka M, et al. Treatment for Fisher syndrome, Bickerstaff's brainstem encephalitis and related disorders. *Cochrane Database Syst Rev* 2007; **1**: CD004761.
- 107) Katz U, Achiron A, Sherer Y, Shoenfeld Y. Safety of intravenous immunoglobulin (IVIg) therapy. *Autoimmun Rev* 2007; **6**: 257-9.
- 108) Wolberg AS, Kon RH, Monroe DM, Hoffman M.

- Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations. *Am J Hematol* 2000; **65**: 30-4.
- 109) Hefer D, Jaloudi M. Thromboembolic events as an emerging adverse effect during high-dose intravenous immunoglobulin therapy in elderly patients: a case report and discussion of relevant literature. *Ann Hematol* 2005; **84**: 411-5.
- 110) Reinhart WH, Berchtold PE. Effect of high-dose intravenous immunoglobulin therapy on blood rheology. *Lancet* 1992; **339**: 662-4.
- 111) Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. *Ann Int Med* 1994; **121**: 259-62.
- 112) Sati HI, Ahya R, Watson HG. Incidence and associations of acute renal failure complicating high-dose intravenous immunoglobulin therapy. *Br J Haematol* 2001; **113**: 556-7.
- 113) Gupta N, Ahmed I, Nissel-Horowitz S, et al. Intravenous gammaglobulin-associated acute renal failure. *Am J Hematol* 2001; **66**: 151-2.
- 114) Miller JLC, Petteway SR, Douglas CL. Ensuring the pathogen safety of intravenous immunoglobulin and other human plasma-derived therapeutic proteins. *J Allergy Clin Immunol* 2001; **108**: S91-4.

Correspondence: Dr. Giancarlo Maria Liumbruno,
Viale Italia, 19
57126 Livorno, Italy
E-mail: giancarlo@liumbruno.it

Appendix A

Working methods of the study group and grades of recommendation

The process of developing these Recommendations, in compliance with the indications contained in the methodological manual of National Programme for Guidelines¹, was based on a systematic review of the literature and updating of existing recommendations on the subject: the recommendations will be discussed in a multidisciplinary context in a subsequent stage and in the relevant institutions. Furthermore, an explicit evaluation of the quality of the proof and the strength with which the single recommendations are adopted and implemented is provided¹.

The methodology used to prepare the grades of recommendations was drawn from that used by the Consensus Conference of the American College of Chest Physicians in 2004².

The recommendations are classified by **grade**, expressed in Arabic numbers (1,2), according to their strength, and in **letters** (A, B, C), according to the evidence and type of study.

In detail (Table I):

- **Grade 1:** the authors are certain that the benefits are greater (or less) than the costs in terms of risk and financial expenditure. This is, therefore, a strong **recommendation**.
 - **Grade 2:** the authors are less certain concerning the above points and, therefore, make a weaker recommendation.
- As far as regards the classification by letters:
- **Grade A:** a recommendation derived from the evidence of numerous, consistent randomised studies.
 - **Grade C+:** a recommendation derived from the analysis of observational clinical studies, but with very consistent results, or from results unequivocally extrapolated from randomised studies.
 - **Grade B:** the clinical studies providing the evidence were randomised, but had important limitations (discordant results, methodological flaws).

- **Grade C:** the recommendation derives from an analysis of observational studies, with less consistent results, or from results extrapolated with a lower degree of certainty from randomised studies; recommendations based on the clinical experience/opinion of experts are also classified as grade C.

The verb "*recommend*" is used for the higher grades (1A, 1C+, 1B, 1C), while the verb "*suggest*" is used for the lower grades (2A, 2C+, 2B and 2C).

In general, any recommendation other than Grade 1A implies that the authors recognise that there are alternative interpretations of the available evidence and that there are other clinical policies that can reasonably be considered appropriate. Furthermore, even the Grade 1A recommendations cannot be applied indiscriminately in every circumstance and in every patient.

The conventional classification of evidence is based on mathematical and statistical criteria, assigning the "strength" of evidence, in order, to: meta-analysis, randomised, controlled, experimental studies, retrospective analyses, prospective follow-ups, transverse population studies, reviews, anecdotal evidence. This is correct as far as concerns the purely clinical studies, particularly therapeutic studies focused on objective outcome evaluations.

In some fields the recommendations remain weak; in others, however, data from clinical studies that have been carried out with methodological rigour in a sufficiently large population have enabled the formulation of specific and more certain recommendations.

Furthermore, it is not always possible to use the aggregated data from meta-analyses: these variables increase the margins of individual decision for each doctor and for each patient.

The recommendations are accompanied by indicators intended to enable clinical auditing¹.

The present document will be revised annually, to include new information that has become available in the meantime.

Each member making up the study group has signed a statement declaring a lack of conflict of interests, conforming with that adopted by the National Programmed for Guidelines¹.

References

- 1) Istituto Superiore di Sanità, Agenzia per i Servizi Sanitari Regionali. *Programma Nazionale per le Linee Guida –Manuale Metodologico*, Milano, Italia, Arti Grafiche Passoni srl; 2002. Available at: http://www.pnlg.it/doc/Manuale_PNLG.pdf.
- 2) Guyatt G, Schünemann HJ, Cook D, et al. Applying the grades of recommendation for antithrombotic and thrombolytic therapy. *Chest* 2004; **126**: S179-87.

Table I - Grades of Recommendations

Grade of Recommendation	Clarity of Risk /Benefit	Methodological strength of supporting evidence	Implications
1A	Clear	Randomised controlled trials without important limitations	Strong recommendation; can apply to most patients in most circumstances without reservation
1C+	Clear	No randomised controlled trials but strong results from randomised controlled trials can be unequivocally extrapolated, or overwhelming evidence from observational studies	Strong recommendation; can apply to most patients in most circumstances
1B	Clear	Randomised controlled trials with important limitations (inconsistent results, methodological flaws)	Strong recommendations; likely to apply to most patients
1C	Clear	Observational studies	Intermediate-strength recommendation; may change when stronger evidence is available
2A	Unclear	Randomised controlled trials without important limitations	Intermediate-strength recommendation; best action may differ depending on circumstances or patients' or societal values
2C+	Unclear	No randomised controlled trials but strong results from randomised controlled trials can be unequivocally extrapolated, or overwhelming evidence from observational studies	Weak recommendation; best action may differ depending on circumstances or patients' or societal values
2B	Unclear	Randomised controlled trials with important limitations (inconsistent results, methodological flaws)	Weak recommendation; alternative approaches likely to be better for some patients under some circumstances
2C	Unclear	Evidence obtained from respected authorities or from expert committee reports or opinion of the group of experts responsible for these recommendations	Very weak recommendations; other alternatives may be equally reasonable